Navigation Links
Adenoscan(R) Patent Lawsuits Settled
Date:10/22/2007

ectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(R), Neurontin(R), Lotrel(R), and Famvir(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative produ
'/>"/>
SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Indian Doctor granted US patent on organ regeneration
2. Dr Reddy’s Laboratories to challenge patents on drug
3. Yoga, ayurveda being documented to stop patent misuse
4. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
5. US Court Rules Against Lupin in Ramipril Patent Case
6. HIV Patients Opposes Patenting Of AIDS Drug
7. Provigil Patent Extension Accorded To Cephalon
8. AIDS Sufferers Protest against Proposed Patent for Tenofovir
9. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
10. Venus Remedies Files 5th International Patent Application
11. Patent for Seminal RNAi innovation Cleared in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... September 16, 2014 Cliff Lake Dental Care ... Kristaleen is the newest dental hygienist to join Dr. Rauchwarter's ... to working with her and knows she will bring many ... , Kristaleen grew up in River Falls, WI. She ... College in 2003 and practiced dental assisting in the Twin ...
(Date:9/16/2014)... in helping people to reach their fitness and ... wearers improve their wellness by constantly monitoring their ... into companion computer programs and mobile apps. ... for these devices, researchers at the University of ... these activity monitors, such as those made by ...
(Date:9/16/2014)... CO (PRWEB) September 16, 2014 Aspen ... that it has been recognized for its high morale ... Consulting magazine “The Best Small Firms to Work For ... survey annually, with more than 10,000 consultants participating across ... Extensive employee satisfaction surveys were conducted, and firms were ...
(Date:9/16/2014)... September 14, 2014 A new study found ... (SB) stenting of true coronary bifurcation lesions yields ... The DKCRUSH-VI clinical trial is the first study ... Findings were reported today at the 26th annual ... the Cardiovascular Research Foundation (CRF), TCT is the ...
(Date:9/16/2014)... with endocrine therapy and radiation therapy as part ... care for women with hormone-receptor positive (HR+) invasive ... Fox Chase Cancer Center, however, shows that combination ... with the disease. , The results, which ... for Radiation Oncology,s 56th Annual Meeting on Sunday, ...
Breaking Medicine News(10 mins):Health News:Cliff Lake Dental Care Announces Newest Team Member 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3
... patients covered by compensation have worse physical and life-quality ... to new research. ,Orthopaedic injury, usually ... form of hospitalisation in Australia, according to the study ... ,,The authors Professor Peter Cameron, Head of ...
... health doctors argue for routine opt-out HIV testing in ... departments and hospital wards. ,In the first article, ... people in the UK with HIV do not know they ... for pregnant women and people attending genitourinary (GUM) clinics. ...
... taken before meals, can improve blood glucose control for people ... with short-acting injected insulin that is taken in addition ... according to a new review of the body of published ... 2 diabetes typically have to take extra insulin at mealtimes ...
... AVGO), a late stage biotechnology company that develops central ... selection of the optimal dose of HD-02, its ... ,This dose was determined in an open-label ... Dr. Diana Rosas of Massachusetts General Hospital (MGH), and ...
... mass displacement of people in sub-Saharan Africa do not necessarily ... refugee agency said on Friday. ,Contradicting a ... the UN High Commissioner for Refugees (UNHCR) said that out ... actually had a lower rate than surrounding host communities. ...
... who was detained for 30 years in his native Cuba, realized ... a ceremony in Miami. ,Now, he says, his ... the former fisherman is convinced he will outlive the ailing Cuban ... far less healthy than I am, he can hardly talk," Temprana ...
Cached Medicine News:Health News:Doctors Call for Opt-out Approach to HIV Testing 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 3Health News:Avicena to Advance Huntington's Disease Clinical Program into Phase III 2Health News:No Clear Link Between Conflict, Rape and HIV: UN Study 2Health News:The American Dream Comes True for 105-year-old Cuban 2
(Date:9/16/2014)... , Sept. 16, 2014 Chindex International, ... ) announced that, at a special meeting of stockholders ... merger agreement (the "Merger  Agreement") by and among the ... Acquisition, Inc. ("Merger Sub"). Parent is an affiliate of ... Ms. Roberta Lipson , the CEO of the ...
(Date:9/16/2014)... Research and Markets has announced the addition of the ... offering. Animal vaccines are biological preparations used ... prepared from weakened or dead microbes that can cause a ... animal vaccines are also formulated using a part of a ... These components act as stimulating agents that trigger ...
(Date:9/16/2014)... 16, 2014 QPID Health , a leader ... headquarters in Boston and their first ... be at 175 Franklin Street in Boston ... QPID Health,s new Southern California office ... expansion will help meet the demands of customers nationwide.  Both ...
Breaking Medicine Technology:Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... Switzerland, June 23 Debiopharm Group,(Debiopharm), a Swiss-based global ... of prescription drugs that target unmet medical,needs, announced that ... was launched in Germany in May 2009, by Dr ... on a preliminary basis in,Belgium. The effective commercial launch ...
... --Whole-Genome Searches Are Revealing Secrets of a Childhood Cancer-- , ... The Children,s Hospital of Philadelphia advance the search for genetic ... childhood cancer. , , Originating in the peripheral nervous ... childhood and causes 15 percent of all childhood cancer deaths. ...
Cached Medicine Technology:Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 3Gene Findings Unlocking Reasons for Neuroblastoma Risk 4
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Medicine Products: